fgf1 + CPP-C

**fgf1 + CPP-C** is a combination therapeutic candidate formulated from *fibroblast growth factor 1 (FGF1)* and a specific cell-penetrating peptide called CPP-C. FGF1 is a naturally occurring growth factor involved in cell proliferation, differentiation, and metabolic regulation, particularly glucose metabolism, insulin sensitivity, and β-cell protection. In various studies, FGF1 demonstrates ability to lower blood glucose, improve insulin resistance, and protect pancreatic β-cells without causing hypoglycemia, making it a promising agent for metabolic disorders like Type 2 diabetes. CPP-C is a synthetic peptide designed to enhance the intracellular delivery of therapeutic agents, meaning this combination may improve FGF1’s bioavailability and cellular uptake compared to FGF1 alone. This formulation is experimental, and there is no evidence it has an approved commercial product. The primary focus of preclinical research on such combinations is to improve the pharmacokinetics and tissue-specific activity of FGF1, offering potential for greater efficacy in difficult-to-treat forms of diabetes and possibly other metabolic diseases[1].

Other names

fgf1 + CPP-C